Mascaux C - Search Results

1

TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma.

Staumont B, Jamakhani M, Costa C, Vandermeers F, Sriramareddy SN, Redouté G, Mascaux C, Delvenne P, Hubert P, Safari R, Willems L. Staumont B, et al. Among authors: mascaux c. Cancers (Basel). 2020 Jun 6;12(6):1484. doi: 10.3390/cancers12061484. Cancers (Basel). 2020. PMID: 32517259 Free PMC article.

2

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L. Vandermeers F, et al. Among authors: mascaux c. Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351772

3

Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.

Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L. Hubaux R, et al. Among authors: mascaux c. Eur J Cancer. 2010 Jun;46(9):1724-34. doi: 10.1016/j.ejca.2010.03.021. Epub 2010 May 5. Eur J Cancer. 2010. PMID: 20451370

4

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L. Hubaux R, et al. Among authors: mascaux c. ERJ Open Res. 2015 Oct 19;1(2):00028-2015. doi: 10.1183/23120541.00028-2015. eCollection 2015 Oct. ERJ Open Res. 2015. PMID: 27730151 Free PMC article.

5

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M. Reita D, et al. Among authors: mascaux c. Cancers (Basel). 2021 Sep 30;13(19):4926. doi: 10.3390/cancers13194926. Cancers (Basel). 2021. PMID: 34638411 Free PMC article. Review.

6

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party.

Berghmans T, Ameye L, Lafitte JJ, Colinet B, Cortot A, CsToth I, Holbrechts S, Lecomte J, Mascaux C, Meert AP, Paesmans M, Richez M, Scherpereel A, Tulippe C, Willems L, Dernies T, Leclercq N, Sculier JP; European Lung Cancer Working Party. Berghmans T, et al. Among authors: mascaux c. Front Oncol. 2015 Jan 28;4:386. doi: 10.3389/fonc.2014.00386. eCollection 2014. Front Oncol. 2015. PMID: 25674536 Free PMC article.

7

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C. Boyer A, et al. Among authors: mascaux c. Eur Respir Rev. 2018 Mar 14;27(147):170098. doi: 10.1183/16000617.0098-2017. Print 2018 Mar 31. Eur Respir Rev. 2018. PMID: 29540495 Free PMC article. Review.

8

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M. Reita D, et al. Among authors: mascaux c. Cancers (Basel). 2022 Mar 4;14(5):1321. doi: 10.3390/cancers14051321. Cancers (Basel). 2022. PMID: 35267628 Free PMC article. Review.

9

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.

Berghmans T, Ameye L, Willems L, Paesmans M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB, Cstoth I, Dernies T, Toussaint L, Leclercq N, Sculier JP; European Lung Cancer Working Party. Berghmans T, et al. Among authors: mascaux c. Lung Cancer. 2013 Nov;82(2):340-5. doi: 10.1016/j.lungcan.2013.07.020. Epub 2013 Aug 7. Lung Cancer. 2013. PMID: 24007627

10

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC).

Dhont L, Pintilie M, Kaufman E, Navab R, Tam S, Burny A, Shepherd F, Belayew A, Tsao MS, Mascaux C. Dhont L, et al. Among authors: mascaux c. BMC Cancer. 2018 Apr 16;18(1):429. doi: 10.1186/s12885-018-4215-y. BMC Cancer. 2018. PMID: 29661164 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

116 results

Search Page